Kenta Yoshida

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 39

Top Topics

Estrogen Receptor

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Clinical cancer research : an official journal of the American Association for Cancer Research

Nature reviews. Drug discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Joy C Hsu, Michael Wu, Chloe Kim, Bianca Vora, Yi Ting Kayla Lien, Ashutosh Jindal, Kenta Yoshida, Sonoko Kawakatsu, Jeremy Gore, Jin Yan Jin, Christina Lu, Bingyuan Chen, Benjamin Wu
Applications of Advanced Natural Language Processing for Clinical Pharmacology. Clinical pharmacology and therapeutics 115 (4) (2024)
Joy C Hsu, Michael Wu, Chloe Kim, Bianca Vora, Yi Ting Kayla Lien, Ashutosh Jindal, Kenta Yoshida, Sonoko Kawakatsu, Jeremy Gore, Jin Yan Jin, Christina Lu, Bingyuan Chen, Benjamin Wu
Applications of Advanced Natural Language Processing for Clinical Pharmacology. Clinical pharmacology and therapeutics 115 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Aleksandra Galetin, Kim L R Brouwer, Donald Tweedie, Kenta Yoshida, Noora Sjöstedt, Lauren M Aleksunes, Xiaoyan Chu, Raymond Evers, Michael J Hafey, Yurong Lai, Pär Matsson, Andrew M Riselli, Hong Shen, Alex Sparreboom, Manthena V S Varma, Jia Yang, Xinning Yang, Sook Wah Yee, Maciej J Zamek-Gliszczynski, Lei Zhang, Kathleen M Giacomini
Membrane transporters in drug development and as determinants of precision medicine. Nature reviews. Drug discovery 23 (4) (2024)
Aleksandra Galetin, Kim L R Brouwer, Donald Tweedie, Kenta Yoshida, Noora Sjöstedt, Lauren M Aleksunes, Xiaoyan Chu, Raymond Evers, Michael J Hafey, Yurong Lai, Pär Matsson, Andrew M Riselli, Hong Shen, Alex Sparreboom, Manthena V S Varma, Jia Yang, Xinning Yang, Sook Wah Yee, Maciej J Zamek-Gliszczynski, Lei Zhang, Kathleen M Giacomini
Membrane transporters in drug development and as determinants of precision medicine. Nature reviews. Drug discovery 23 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Aleksandra Galetin, Kim L R Brouwer, Donald Tweedie, Kenta Yoshida, Noora Sjöstedt, Lauren M Aleksunes, Xiaoyan Chu, Raymond Evers, Michael J Hafey, Yurong Lai, Pär Matsson, Andrew M Riselli, Hong Shen, Alex Sparreboom, Manthena V S Varma, Jia Yang, Xinning Yang, Sook Wah Yee, Maciej J Zamek-Gliszczynski, Lei Zhang, Kathleen M Giacomini
Membrane transporters in drug development and as determinants of precision medicine. Nature reviews. Drug discovery (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Aleksandra Galetin, Kim L R Brouwer, Donald Tweedie, Kenta Yoshida, Noora Sjöstedt, Lauren M Aleksunes, Xiaoyan Chu, Raymond Evers, Michael J Hafey, Yurong Lai, Pär Matsson, Andrew M Riselli, Hong Shen, Alex Sparreboom, Manthena V S Varma, Jia Yang, Xinning Yang, Sook Wah Yee, Maciej J Zamek-Gliszczynski, Lei Zhang, Kathleen M Giacomini
Membrane transporters in drug development and as determinants of precision medicine. Nature reviews. Drug discovery 23 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology 13 (4) (2024)
Joy C Hsu, Michael Wu, Chloe Kim, Bianca Vora, Yi Ting Kayla Lien, Ashutosh Jindal, Kenta Yoshida, Sonoko Kawakatsu, Jeremy Gore, Jin Yan Jin, Christina Lu, Bingyuan Chen, Benjamin Wu
Applications of Advanced Natural Language Processing for Clinical Pharmacology. Clinical pharmacology and therapeutics 115 (4) (2024)
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie W Chinn, Matts Kågedal
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab. CPT: pharmacometrics & systems pharmacology (2024)
Kenta Yoshida, Allan Jaochico, Jialin Mao, Dewakar Sangaraju
Glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC-0810 in humans. British journal of clinical pharmacology (2023)
Kenta Yoshida, Allan Jaochico, Jialin Mao, Dewakar Sangaraju
Glycochenodeoxycholate and glycodeoxycholate 3-O-glucuronides, but not hexadecanedioate and tetradecanedioate, detected weak inhibition of OATP1B caused by GDC-0810 in humans. British journal of clinical pharmacology (2023)
Joy C Hsu, Michael Wu, Chloe Kim, Bianca Vora, Yi Ting Kayla Lien, Ashutosh Jindal, Kenta Yoshida, Sonoko Kawakatsu, Jeremy Gore, Jin Yan Jin, Christina Lu, Bingyuan Chen, Benjamin Wu
Applications of Advanced Natural Language Processing for Clinical Pharmacology. Clinical pharmacology and therapeutics (2023)
Logan Brooks, Michael Dolton, Jurgen Langenhorst, Kenta Yoshida, Yi Ting Kayla Lien, Vikram Malhi, Chunze Li, Pablo Perez-Moreno, John Bond, Ya-Chi Chen, Jiajie Yu
Concentration QTc analysis of giredestrant: Overcoming QT/heart rate confounding in the presence of drug-induced heart rate changes. Clinical and translational science (2023)
Rashed Harun, Rucha Sane, Kenta Yoshida, Dhruvitkumar S Sutaria, Jin Yan Jin, James Lu
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation. JCO clinical cancer informatics 7 (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
Logan Brooks, Michael Dolton, Jurgen Langenhorst, Kenta Yoshida, Yi Ting Kayla Lien, Vikram Malhi, Chunze Li, Pablo Perez-Moreno, John Bond, Ya-Chi Chen, Jiajie Yu
Concentration QTc Analysis of Giredestrant: Overcoming QT/HR Confounding in the Presence of Drug-Induced Heart Rate Changes. Clinical and translational science (2023)
Sharon M Rymut, Lindsay M Henderson, Victor Poon, Tracy L Staton, Fang Cai, Siddharth Sukumaran, Horace Rhee, Ryan Owen, Saroja Ramanujan, Kenta Yoshida
A mechanistic PK/PD model to enable dose selection of the potent anti-tryptase antibody (MTPS9579A) in patients with moderate-to-severe asthma. Clinical and translational science (2023)
Rashed Harun, Rucha Sane, Kenta Yoshida, Dhruvitkumar S Sutaria, Jin Yan Jin, James Lu
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation. JCO clinical cancer informatics 7 (2023)
Rashed Harun, Rucha Sane, Kenta Yoshida, Dhruvitkumar S Sutaria, Jin Yan Jin, James Lu
Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation. JCO clinical cancer informatics 7 (2023)
Elise Oh, Russ Wada, Kha Le, Yanan Zheng, Jin Jin, Victor Poon, Kit Wong, Ryan Owen, Kenta Yoshida
PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria. CPT: pharmacometrics & systems pharmacology (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Joy C Hsu, Michael Wu, Chloe Kim, Bianca Vora, Yi Ting Kayla Lien, Ashutosh Jindal, Kenta Yoshida, Sonoko Kawakatsu, Jeremy Gore, Jin Yan Jin, Christina Lu, Bingyuan Chen, Benjamin Wu
Applications of Advanced Natural Language Processing for Clinical Pharmacology. Clinical pharmacology and therapeutics (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (6) (2023)
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, Francois Mercier, Pascal Chanu, Benjamin Wu, Anthony Lee, Chunze Li, Jin Yan Jin, Michael L Maitland, Martin Reck, Mark A Socinski
Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Kenta Yoshida, Phyllis Chan, Mathilde Marchand, Rong Zhang, Benjamin Wu, Marcus Ballinger, Nitzan Sternheim, Jin Y Jin, René Bruno
Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study. The AAPS journal 24 (3) (2022)
Chin Wong, Ajit Dash, Jill Fredrickson, Nicholas Lewin-Koh, Shan Chen, Kenta Yoshida, Yanqiu Liu, Johnny Gutierrez, Rebecca Kunder
Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial. Hepatology (Baltimore, Md.) (2022)
Kunal S Taskar, Xinning Yang, Sibylle Neuhoff, Mitesh Patel, Kenta Yoshida, Mary F Paine, Kim L R Brouwer, Xiaoyan Chu, Yuichi Sugiyama, Jack Cook, Joseph W Polli, Imad Hanna, Yurong Lai, Maciej Zamek-Gliszczynski, null null
Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. Clinical pharmacology and therapeutics 112 (3) (2022)
Tatsuki Mochizuki, Yasunori Aoki, Takashi Yoshikado, Kenta Yoshida, Yurong Lai, Hideki Hirabayashi, Yoshiyuki Yamaura, Kevin Rockich, Kunal Taskar, Tadayuki Takashima, Xiaoyan Chu, Maciej J Zamek-Gliszczynski, Jialin Mao, Kazuya Maeda, Kenichi Furihata, Yuichi Sugiyama, Hiroyuki Kusuhara
Physiologically-based pharmacokinetic model-based translation of OATP1B-mediated drug-drug interactions from coproporphyrin I to probe drugs. Clinical and translational science 15 (6) (2022)
Xiaoyan Chu, Bhagwat Prasad, Sibylle Neuhoff, Kenta Yoshida, James Steven Leeder, Dwaipayan Mukherjee, Kunal S Taskar, Manthena V S Varma, Xinyuan Zhang, Xinning Yang, Aleksandra Galetin
Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. Clinical pharmacology and therapeutics 112 (3) (2022)
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang, Alyse Lin, Benjamin Wu, Marcus Ballinger, Nitzan Sternheim, Jin Y Jin, René Bruno
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework. CPT: pharmacometrics & systems pharmacology 10 (10) (2021)
Kenta Yoshida, Justin Wilkins, Julia Winkler, Janet R Wade, Naoki Kotani, Nina Wang, Rucha Sane, Pascal Chanu
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. Journal of clinical pharmacology 61 (12) (2021)
Kit Wun Kathy Cheung, Kenta Yoshida, Sravanthi Cheeti, Buyun Chen, Roland Morley, Iris T Chan, Srikumar Sahasranaman, Lichuan Liu
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study. Drug metabolism and disposition: the biological fate of chemicals 47 (9) (2019)
Xiaoyan Chu, Mingxiang Liao, Hong Shen, Kenta Yoshida, Arik A Zur, Vikram Arya, Aleksandra Galetin, Kathleen M Giacomini, Imad Hanna, Hiroyuki Kusuhara, Yurong Lai, David Rodrigues, Yuichi Sugiyama, Maciej J Zamek-Gliszczynski, Lei Zhang, null null
Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clinical pharmacology and therapeutics 104 (5) (2019)